---
title: "Adicet Bio, Inc. Provides Corporate Update and Highlights 2026 Milestones"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271796918.md"
description: "Adicet Bio, Inc. provided a corporate update on January 7, 2026, highlighting significant advancements in its clinical programs and key milestones for the year. Notable achievements include doubling enrollment in the prula-cel Phase 1 program to over 20 patients, FDA alignment for outpatient dosing in lupus trials, and an expected regulatory filing for ADI-212 in prostate cancer in the first half of 2026. The company also extended its cash runway into the second half of 2027 following a $74.8 million equity offering and plans to initiate a pivotal study for prula-cel in the second half of 2026, pending FDA clearance."
datetime: "2026-01-07T13:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271796918.md)
  - [en](https://longbridge.com/en/news/271796918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271796918.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271796918.md) | [繁體中文](https://longbridge.com/zh-HK/news/271796918.md)


# Adicet Bio, Inc. Provides Corporate Update and Highlights 2026 Milestones

**On January 7, 2026, Adicet Bio, Inc. announced significant progress in its clinical programs and outlined key milestones for 2026.**

**Key Highlights:**

-   Enrollment in prula-cel Phase 1 program doubled to over 20 patients by Dec 31, 2025.
-   FDA alignment achieved for outpatient dosing in lupus nephritis and systemic lupus erythematosus trials.
-   Regulatory filing for ADI-212 in prostate cancer expected in 1H/2026.
-   Cash runway extended into 2H/2027 following a $74.8 million equity offering.
-   Plans to initiate pivotal study for prula-cel in 2H/2026, subject to FDA clearance.

Original SEC Filing: Adicet Bio, Inc. \[ ACET \] - 8-K - Jan. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [Adicet Bio, Inc. (ACET.US)](https://longbridge.com/en/quote/ACET.US.md)

## Related News & Research

- [Analog Devices Insider Makes High-Value Move With Fresh Stock Sale](https://longbridge.com/en/news/277882657.md)
- [Orion Porfolio Solutions LLC Has $10.54 Million Stock Position in Analog Devices, Inc. $ADI](https://longbridge.com/en/news/278087161.md)
- [DoubleLine Yield Opportunities Fund declares March 2026 distribution](https://longbridge.com/en/news/277487844.md)
- [Tesla Physical AI: The Sovereign Architect of Robotics in 2026](https://longbridge.com/en/news/277656956.md)
- [Az cancels adjourned 2026 special meeting after quorum shortfall](https://longbridge.com/en/news/277990639.md)